ArriVent BioPharmaAVBP
Recorded

ArriVent BioPharma Study update

Review the key takeaways and the transcript of this earnings call.

Period 0Duration47 minParticipants16

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Good morning, everyone, and welcome to the ArriVent BioPharma virtual webinar. At this time, all attendees are in a listen-only mode, and a question and answer session will follow the presentation. To our analysts joining us live, we kindly ask that you limit yourself to one question and one follow-up. As a reminder, this call is being recorded, and a replay will be made available on the ArriVent website following the conclusion of the event. I'd now like to turn the call over to Winston Kung, Chief Financial Officer at ArriVent BioPharma. Please go ahead, Winston. Great.

Winston KungCFO

Thank you, Tara. Before we start the presentation, I want to make note that this webinar may include forward-looking statements under the PSLRA. Actual results may differ materially from those projected in the forward-looking statements. Additional information concerning factors that could cause materially different results includes forward-looking statements in our periodic reports filed with the SEC and available on our website. With that, I'd like to turn it over to our CEO, Dr. Bing Yao.

Bing YaoCEO

Thank you, Winston, and good morning, everyone. Thank you for joining us today. We are very pleased to host this investor call following the presentation of our phase I clinical data for ARR-217 at ESMO. We are particularly excited that this data was selected for late-breaking oral presentation. Before we dive into the clinical results, I would like to briefly put ARR-217 into the context of ArriVent's broad strategy and pipeline. Next slide, please. Next. As you can see on this slide, we have built a diversified oncology pipeline spanning targeted small molecule and antibody drug conjugates with multiple opportunities across indications and geographies. Starting with firmonertinib, we continue to advance our global phase III ALPACCA trial in patients with EGFR PACC mutant non-small cell lung cancer. Enrollment remains ongoing, and we believe this program represents an important opportunity to address significant unmet medical needs.

Bing YaoCEO

At the same time, we have made substantial progress in building a differentiated ADC portfolio, which has become an increasingly important part of our long-term growth strategy. We now have four ADC programs in our pipeline, including two in clinical development and two earlier stage programs. I'm also pleased to highlight that we recently enrolled the first patient in our phase I trial of ARR-002, our novel dual targeting ADC, directed against NaPi2b and MUC16. This represents another important milestone in the advancement of our ADC pipeline. Turning to ARR-217, the focus on today's call. This is our CDH17 targeted ADC being developed for gastrointestinal cancers, particularly colorectal cancer. Yesterday's ESMO presentation represent an important milestone for the program. We are very encouraged by the emerging clinical data, particularly the anti-tumor activity and the tolerability observed to date.

Bing YaoCEO

We believe these results provide a strong foundation for further development and reinforce our confidence in the potential of ARR-217. More broadly, our strategy remains on identifying and advancing differentiated oncology therapies with a goal of delivering meaningful benefits to patients and creating long-term value. With that, let me turn it over to Stuart to discuss our ADC strategy.

Stuart LutzkerPresident of Research and Development

Yeah. Thank you, Bing. Next slide. Next slide, please. Our ADC strategy is to identify and develop therapeutically important ADCs based on the pattern of ADC target expression. For ADC targets that have high homogeneous tumor expression, such as CDH17, which we will discuss today, we pursue differentiated molecules with design features such as conjugation method, linker, and payload for best-in-class ADC potential in tumors with high unmet medical need, many of which are still treated with standard chemotherapy. For ADC targets that have a high but more heterogeneous expression, which is actually more common in solid tumors, we are developing a pipeline of novel tetravalent dual targeting ADCs. As Bing mentioned, we are very excited that our first tetravalent dual targeting ADC, ARR-002, is in phase I dose escalation in the U.S.

Stuart LutzkerPresident of Research and Development

These dual targeting ADCs are designed to overcome resistance that can arise from tumor cells present within the tumor mass that have lower expression and that can lead to resistance. In this way, dual targeting ADCs have the potential to more completely treat the entire tumor and all sites of disease, and also decreases the need for IHC-based companion diagnostic to select patients such as in folate receptor high ovarian cancer. The tetravalent ADC design also increases the binding and internalization of the ADC to tumor cells to provide superior drug delivery and enhance cytotoxicity over bivalent ADCs. Next slide. As I mentioned, CDH17 is an ideal target for single targeting ADCs as it has high homogeneous expression in colorectal cancer, which as you can see, the vast majority of colorectal tumors exhibiting greater than 75% of the tumor cells having high IHC 3+ staining. Next slide. ARR-217 is our novel CDH17-targeting ADC we are developing together with Lepu Biopharma.

Stuart LutzkerPresident of Research and Development

ARR-217 consists of a novel high-affinity humanized anti-CDH17 monoclonal antibody directed against the most exposed extracellular domain of CDH17, which includes a potent TOP1 inhibitor exatecan payload. Exatecan is less subject to drug efflux pumps such as P-gp than other TOP1 inhibitors. Site-specific conjugation is achieved through a stable glycan-based linkage utilizing a hydrophilic linker to improve the PK properties of the molecule. ARR-217 exhibits rapid internalization and enhanced bystander activity in tumor cell lines and robust anti-tumor activity in multiple xenograft models with a range of CDH17 expression. ARR-217 was well-tolerated in monkey studies at the highest dose tested, with minimal GI toxicity, conferring a favorable preclinical therapeutic index. Next slide. To demonstrate the enhanced stability of glycan-based site-specific conjugation, ARR-217 and a control ADC consisting of the same antibody but with conventional cysteine-based conjugation to DXd were incubated in non-human primate plasma.

Stuart LutzkerPresident of Research and Development

As you can see, there was minimal release of the payload from ARR-217 during this 21-day period compared to the DXd control. Next slide. ARR-217 with DAR4 exatecan exhibited improved bystander activity compared to the DAR8 DXd control ADC, as you can see in this figure, with near complete killing of non-CDH17-expressing cells, here demonstrated utilizing two different cell line models. Next slide. ARR-217 induced tumor regression across a range of xenograft models with different CDH17 expression. The activity of ARR-217 was comparable or improved over ARR-217 DXd control. This is despite ARR-217 having a lower DAR. Together, this data demonstrates the best-in-class potential of ARR-217 in colorectal cancer.

Stuart LutzkerPresident of Research and Development

I'll now hand things over to Preeti to discuss the clinical development of ARR-217.

Preethi ShakerVP of Clinical Development

Thank you, Stuart. Next slide. Colorectal cancer continues to represent one of the largest unmet needs in oncology today. Globally, nearly 1.9 million patients are diagnosed each year, and the incidence is expected to grow substantially, reaching approximately 3 million cases annually by 2040. Despite advances in treatment, colorectal cancer remains the second leading cause of cancer-related death worldwide, and outcomes are particularly poor for patients with metastatic colorectal cancer. The current five-year survival rate is only about 13%, underscoring the need for more effective therapies that can meaningfully extend survival and improve quality of life. Next slide. This slide highlights the current treatment landscape for metastatic colorectal cancer. Today, treatment selection is guided by molecular profiling with patients stratified across key biomarker-defined populations, including KRAS, RAS mutant, BRAF mutant, MSI-high, and HER2-amplified disease.

Preethi ShakerVP of Clinical Development

In the first and second-line setting, the majority of patients receive chemotherapy backbone such as FOLFOX or FOLFIRI, often combined with biological agents. Despite the increasing use of biomarker-directed therapies earlier in treatment, options become much more limited after progression, with treatments that generally provide modest clinical benefit. Next slide. Current third-line and later treatment options for metastatic colorectal cancer provide limited benefit. This slide summarizes the efficacy of the currently available standards of care for metastatic colorectal cancer after progression on earlier lines of therapy. While several agents are approved and commonly used, the overall outcomes are limited. Objective response rates are in the single digits and are generally only 1%-6%, highlighting the difficulty of generating meaningful tumor shrinkage in this setting. Progression-free survival is typically just two to five months, and the median overall survival remains under a year.

Preethi ShakerVP of Clinical Development

Even the best available regimens provide modest outcomes, highlighting the significant unmet need for more effective therapies. Next slide. ARR-217 is being evaluated in a multicenter phase I study in China and the U.S. in advanced solid tumors, including colorectal cancer. Eligible patients have locally advanced or metastatic solid tumors, have progressed on standard therapies, maintain a good performance status with an ECOG score of 0-1, and have measurable disease according to RECIST criteria. The Phase I-A portion of this study focuses primarily on safety and dose escalation. Patients were enrolled across escalating dose levels, beginning at 2 mgs per kg and advancing through multiple dose cohorts to characterize the safety profile, identify dose limiting toxicities, and establish an appropriate dose range for further development. Additional backfill cohorts were included to evaluate safety and generate preliminary efficacy data at selected dose levels.

Preethi ShakerVP of Clinical Development

The ongoing Phase I-B portion of the study in colorectal cancer, patients are being randomized 1-to-1 between 5 mgs per kg and the 6 mgs per kg dose with safety and ORR as key endpoints. Next slide. As of the August 5, 2026, data cutoff, 123 patients have received ARR-217, including 113 patients with colorectal cancer. The enrolled CRC population reflects a typical metastatic colorectal cancer population. The median age was 58 years, with approximately one-third of patients were female. The majority of patients were ECOG 0-1. This study enrolled a heavily pretreated metastatic CRC population. Patients received a median of 3 prior lines of therapy. Nearly all had received standard chemotherapy agents such as oxaliplatin and irinotecan. Over half of patients had liver metastasis, nearly 60% had RAS mutations, and most had microsatellite stable disease. Next slide. ARR-217 demonstrated predictable dose proportional pharmacokinetics and strong ADC stability.

Preethi ShakerVP of Clinical Development

The ADC and total antibody profiles closely tracked together, while free exatecan exposure remained extremely low. These data suggest efficient payload delivery with minimal systemic payload release. Next slide. Across the 123 patients, the majority of treatment-related adverse events were low-grade. The most commonly observed toxicities were hematological and gastrointestinal in nature, including anemia, neutropenia, diarrhea, nausea, and decreases in white blood cell and platelet counts. While Grade 3 or higher events were observed, they generally occurred more frequently at higher dose levels. Of note, at 6 mgs per kg, the safety was well-tolerated, with only 2% Grade 3 diarrhea and a low rate of hematological toxicities. In addition, there were only 2 dose reductions and no treatment discontinuations due to adverse events at the time of the data cutoff. During dose escalation, the maximum tolerated dose was not reached.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day